Source: http://www.cjnews.com/
MONTREAL – Investigators at the Jewish General Hospital’s (JGH) Lady Davis Institute and the McGill University Health Centre (MUHC) have begun clinical trials that they say may revolutionize the treatment of Type 1 diabetes.
The therapy, pioneered by Dr. Lawrence Rosenberg, aims to regenerate islet cells in the pancreas, thereby restoring normal insulin secretion.
The treatment combines a peptide-based drug, developed by Minneapolis-based pharmaceutical company Exsulin Corporation, which stimulates the growth of insulin-producing cells, and ustekinumab (marketed under the trademark Stelera), an immunosuppressant drug approved for the treatment of psoriasis.
The discovery of the INGAP (islet neogenesis-associated protein) peptide is the result of years of research by Rosenberg, a professor of surgery and medicine at McGill University and, since April, president and CEO of the Integrated Health and Social Services University Network for West-Central Montreal, and his collaborator Dr. Aaron Vinik, director of research and Murray Waitzer Endowed Chair for Diabetes Research at the Eastern Virginia Medical School (EVMS).
Read more: http://www.cjnews.com/living-jewish/health/revolutionary-treatment-of-type-1-diabetes-in-clinical-trials